Last $13.09 USD
Change Today +0.21 / 1.63%
Volume 142.0K
TTPH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

tetraphase pharmaceuticals i (TTPH) Snapshot

Open
$12.93
Previous Close
$12.88
Day High
$13.11
Day Low
$12.67
52 Week High
01/23/14 - $17.74
52 Week Low
04/15/14 - $8.01
Market Cap
339.7M
Average Volume 10 Days
255.3K
EPS TTM
$-2.22
Shares Outstanding
26.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRAPHASE PHARMACEUTICALS I (TTPH)

tetraphase pharmaceuticals i (TTPH) Related Bloomberg News

View More Bloomberg News

tetraphase pharmaceuticals i (TTPH) Related Businessweek News

No Related Businessweek News Found

tetraphase pharmaceuticals i (TTPH) Details

Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative bacteria. The company is conducting a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to-oral step-down therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and preclinical Gram-negative program for multidrug-resistant Gram-negative infections. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

46 Employees
Last Reported Date: 03/6/14
Founded in 2006

tetraphase pharmaceuticals i (TTPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $394.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $293.8K
Chief Medical Officer
Total Annual Compensation: $338.2K
Senior Vice President of Biology
Total Annual Compensation: $273.0K
Compensation as of Fiscal Year 2013.

tetraphase pharmaceuticals i (TTPH) Key Developments

Tetraphase Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Tetraphase Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the second quarter of 2014, the company reported a net loss of $18.5 million or $0.71 per basic and diluted share compared to a net loss of $5.4 million or $0.26 per basic and diluted share for the same period in 2013. Revenues for the second quarter of 2014 were $1.275 million compared to $3.722 million for the same period in 2013. Revenues for each period consisted of contract and grant revenue under three U.S. government awards for the development of Tetraphase compounds as potential countermeasures for the treatment of diseases caused by bacterial biothreat pathogens. The decrease in revenue during the second quarter of 2014 compared to the same period in the prior year was primarily due to timing of activities related to various clinical studies conducted under the company's subcontract with respect to the BARDA award during the quarter ended June 30, 2014, as compared to the quarter ended June 30, 2013. Loss from operations was $18.185 million against $4.958 million a year ago. For the six months, the company reported revenues of $3.732 million against $6.422 million a year ago. Loss from operations was $31.403 million against $7.581 million a year ago. Net loss was $31.986 million or $1.24 per basic and diluted share against $8.217 million or $0.73 per basic and diluted share a year ago.

Tetraphase Pharmaceuticals, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 02:30 PM

Tetraphase Pharmaceuticals, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 02:30 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Guy MacDonald, Chief Executive Officer, President and Director.

Tetraphase Pharmaceuticals, Inc. Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-Abdominal Infections

Tetraphase Pharmaceuticals, Inc. announced that it has completed patient enrollment in IGNITE 1, its Phase 3 clinical trial evaluating the safety and efficacy of eravacycline in the treatment of complicated intra-abdominal infections (cIAI). The company expects to report top-line results from IGNITE 1 in early first quarter 2015. Tetraphase is developing its lead antibiotic candidate, eravacycline, in a Phase 3 global clinical program IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) as a potent new broad-spectrum antibiotic to treat cIAI (IGNITE 1) and cUTI (IGNITE 2), including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC) in September 2013. Eravacycline is the only antibiotic in late-stage development for intravenous and oral dosing against MDR Gram-negative infections. Its broad spectrum activity combined with IV and oral dosing may provide an important treatment option for patients with multidrug-resistant bacterial infections.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTPH:US $13.09 USD +0.21

TTPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TTPH.
View Industry Companies
 

Industry Analysis

TTPH

Industry Average

Valuation TTPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.4x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRAPHASE PHARMACEUTICALS I, please visit www.tphase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.